Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Data-driven clustering studies suggest that conventional diagnostic labels can mask biologically coherent subgroups
Sunscreen alone is not sufficient to prevent new naevi from appearing
Why this matters: First oral PCSK9 inhibitor approved by the FDA Once-daily tablet for adults with hypercholesterolemia, including HeFH Works by blocking PCSK9, helping the liver remove more LDL cholesterol from the bloodstream Offers a convenient alternative to injectable PCSK9 therapies Has the potential to improve long-term adherence and cardiovascular risk management With cardiovascular disease remaining the leading cause of death globally, innovations that make effective therapies easier to use can have a meaningful impact on patient outcomes
As their use has expanded beyond their initial indications, GLP-1 receptor agonists are poised to have more far-reaching societal impacts, influencing aspects of public health, healthcare economics, as well as even social perceptions of obesity and weight management
US$ 23.29
US$ 21.63
US$ 28.45
